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Opinion statement
Bipolar disorder (BD) is a chronic mental illness which follows a relapsing and
remitting course and requires lifetime treatment. The lack of biological markers
for BD is a major difficulty in clinical practice. Exploring multiple endophenotypes
to fit in multivariate genetic models for BD is an important element in the
process of finding tools to facilitate early diagnosis, early intervention, preven-
tion of new episodes, and follow-up of treatment response in BD. Reviewing of
studies on neuroimaging, neurocognition, and biochemical parameters in popula-
tions with high genetic risk for the illness can yield an integrative perspective on
the neurobiology of risk for BD. The most up-to-date data reveals consistent
deficits in executive function, response inhibition, verbal memory/learning, verbal
fluency, and processing speed in risk groups for BD. Functional magnetic reso-
nance imaging (fMRI) studies report alterations in the activity of the inferior
frontal gyrus, medial prefrontal cortex, and limbic areas, particularly in the
amygdala in unaffected first-degree relatives (FDR) of BD compared to healthy
controls. Risk groups for BD also present altered immune and neurochemical
modulation. Despite inconsistencies, accumulating data reveals cognitive and
imaging markers for risk and to a less extent resilience of BD. Findings on neural
modulation markers are preliminary and require further studies. Although the
knowledge on the neurobiology of risk for BD has been inadequate to provide
benefits for clinical practice, further studies on structural and functional changes
in the brain, neurocognitive functioning, and neurochemical modulation have a
potential to reveal biomarkers for risk and resilience for BD. Multimodal, multi-
center, population-based studies with large sample size allowing for homogeneous
subgroup analyses will immensely contribute to the elucidation of biological
markers for risk for BD in an integrative model.
Introduction
Bipolar disorder (BD) is a chronic mental illness
which follows a relapsing and remitting course and
requires lifetime treatment. In nearly two thirds of
patients, the illness begins before the end of the
third decade of life [1]. BD is heritable as shown
by varying (59–93 %) yet high heritability rates [2,
3]. Concordance rates increase substantially from
6 % in dizygotic twins to 43 % in monozygotic
twins [4]. Children of parents with BD are four
times more likely to develop an affective disorder
compared to children of parents with no mental
disorders [5]. Delayed diagnosis and misdiagnosis
are common in BD [6]. Despite evidence for sub-
stantial genetic load in the etiology of BD, clinical
practice still suffers from the absence of biological
markers which could be used in support of the
clinical diagnosis.
Endophenotypes are an important subtype of bio-
markers that have a clear genetic connection and are
more prevalent in patients and in their family mem-
bers [7]. Exploring multiple endophenotypes to fit in
multivariate genetic models for bipolar disorder is an
important element in the process of finding diagnostic
tools to facilitate early intervention and prevention in
BD.
In this review, we aimed to identify common
neurocognitive, neuroanatomical, and neurochemi-
cal abnormalities that may correspond to vulnera-
bility and resilience factors for BD. Literature on
neuroimaging, neurocognition, and biochemical pa-
rameters in BD, particularly in populations with
high genetic risk for the illness, was reviewed to
shed light on the neurobiology of risk for bipolar
disorder from an integrative perspective.
Method
Literature review was completed using keywords Bbipolar disorder,^
Bendophenotype,^ Brisk,^ Brelatives,^ Bneurocognition,^ Bbrain imaging,^
and Boxidative stress.^ Publications were searched using PubMed,
Scopus, Science Direct, and Web of Science electronic databases. Papers
published in English, which involved first-degree relatives (FDR-off-
spring, sibling, co-twins, parents) of a bipolar proband (BD-P) and a
healthy control group with or without a patient group, were included.
Publications with FDR of schizophrenia probands (SCH-P) in addition
to FDR of BD-P, papers on studies modeling for a genetic link to a
proposed biological marker, meta-analysis, and systematic reviews were
also included. In each respective targeted area, individual studies pub-
lished after the most recent meta-analysis and/or systematic review were
included in the review. This article does not publish original research,
animal or human studies, that would need informed consent that
should be carried out by the authors.
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Results
Neurocognition and risk for BD
Genetic influence on measures of various neurocognitive domains has been
well documented [8]. Verbal ability, executive functioning, and psychomotor
processing speed were shown to be highly heritable in familial BD [9]. A large-
scale extended pedigree study suggested impaired processing speed, working
memory, and declarative (facial) memory to be candidate endophenotypes for
BD [10]. After controlling for demography and current mood symptoms,
processing speed was still impaired in BD-P type I and their unaffected FDR,
showing its validity as endophenotype to separate BD-P and FDR from healthy
controls [11].
In search for potential cognitive endophenotypes, a systematic review and
meta-analysis of data from studies on FDR (with or without BD-P) in compar-
ison to healthy controls showed impaired executive function, verbal memory,
and verbal working memory [12, 13]. Among executive functions, response
inhibition deficits were themost robust candidates followed by impaired verbal
memory, sustained attention, and set shifting even after controlling for IQ and
age [14].
More recent studies focusing on healthy adolescent offsprings of parents
with BD found that young FDR have impairments in processing speed and
visual memory [15], cognitive flexibility [16], psychomotor speed, focused
attention, verbal attention, phonemic verbal fluency, short-term memory and
learning [17], verbal intelligence [18], and significantly slower reaction times on
an index of executive attention [19] compared to youth with healthy parents.
Likewise, healthy parents of patients with BD-I had significantly worse perfor-
mance in psychomotor speed, cognitive flexibility, selective attention, response
inhibition, and verbal memory [20, 21] than healthy controls. A recent review
of conscript, cohort, high-risk, family-based and first-episode mania studies
also confirmed that verbal memory and executive function are potential pre-
dictors of BD [22].
Recent studies, however, provide further more nuanced evidence specifically
with regard to impaired response inhibition and interference control in both
adult [23] and adolescent BD-P [24] and their FDR compared to healthy
controls. Other studies found that response inhibition was intact despite in-
creased impulsivity and impulsive decision-making in both familial and non-
familial high-risk groups for BD [25] and interference control was intact in FDR
and co-twins of BD-P [26]. Evidence shows significantly worse response inhi-
bition performance in BD-P I with history of psychotic symptoms and their FDR
compared to controls [27]. Response inhibition deficit was associated with the
process of illness with psychotic features in BD, rather than being a vulnerability
marker [28]. On the other hand, impulsivity as measured by BIS-11 (a self-
report scale) seems to reveal more consistent signals as a candidate
endophenotype both in children, adolescents [29], and adults [25, 30, 31],
and as a predictor of onset of BD in reward-sensitive adolescents and young
adults [32]. However, specificity of impulsivity to BD is questionable as it shows
shared genetic liability with SCH and major depressive disorder [30] and
requires further studies. Risk-taking behavior may also be a potential
endophenotype and predictor of BD [32, 33].
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Recent studies focusing on facial emotion recognition and emotional re-
sponsiveness in at-risk relatives compared to healthy controls showed deficits in
labeling facial emotion, required significantly more time and more intense
emotional information to identify and correctly label face emotions, and were
impaired in other aspects of affective response particularly in inhibiting nega-
tive valenced stimuli and in having greater response bias toward negatively
valenced stimuli [18, 34–39]. Social cognition is another recent area of interest
in defining endophenotypes for BD for which theory of mind (ToM) perfor-
mance has been most commonly considered. BD-FDR performed significantly
worse on the verbal but not visual or higher-order ToM tasks compared to
healthy controls [40]; their performance was comparable to healthy controls on
tasks requiring ToM use and ToM understanding [41].
Do cognitive deficits exist before onset of illness in BD?
Systematic review of data from 23 studies on the premorbid cognitive function
of people who later developed BD and of BD-P when presenting with their first
episode provided evidence that general intelligence is not impaired in the
premorbid stage; however, verbal memory, attention, and executive function
deficits tend to be present during and after the first episode. Data supports the
notion that specific cognitive domain deficits may precede the illness onset in
BD [42•]. However, assessment of premorbid intellectual in BD function may
yield contradictory findings, depending on whether the assessment is retrospec-
tive or prospective [43].
Are the neurocognitive markers specific to BD? Role of psychosis
The genetic etiology of BD and SCH overlap substantially [2]. Enhanced
susceptibility to interference and reduced inhibition [44] as well as
deficits in working memory were reported to be more common in BD
patients with psychosis, in SCH patients, and their FDR compared to
healthy controls [45]. Severity of premorbid intellectual deficit differs
quantitatively between BD and SCH. BD presents significant yet small
premorbid intellectual function deficits when assessed retrospectively but
not prospectively and moderate cognitive impairment after onset of
illness, whereas SCH presents with significant premorbid and large
post-onset impairment [43]. It appears that both disorders are associated
with impaired visual sustained attention which does not differentiate
one condition from another [46].
Further differences between BD and SCH have been observed when
examining the association between single nucleotide polymorphisms
(SNP) in key risk genes in connection to cognitive tests which are
closely linked to prefrontal cortical functioning. The Val66Met polymor-
phism of the brain-derived neurotrophic factor (BDNF) gene is associat-
ed with performance on the Wisconsin Cart Sorting Test in BD but not
in SCH, while the reverse is the case for task performance on the N-back
working memory task [47]. Among previously identified candidate sets
of genes associated with cognitive abilities in SCH or BD visuospatial
attention, verbal abilities sets and delayed verbal memory showed the
strongest enrichments in BD, whereas color-word interference (cognitive
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inhibition) test and sets associated with memory learning slope showed
enrichment in SCH [48].
Testing SCH-FDR and BD-FDR in comparison to healthy controls on
Stroop Color-Word Task and Emotional Stroop Task showed impaired
cognitive inhibition in SCH-FDR but emotional bias toward mood-related
information in BD-FDR [49]. Assessment of executive functions by using
Wisconsin Cart Sorting Test and part A and part B of the Trail Making
Task in SCH, BD, and FDR of both groups revealed familial resemblance
for both tests in BD families, whereas no resemblance was observed in
families with SCH [50]. Using psychosis as a dimension in grouping the
participants, a family study revealed a gradient of performance on the
working and declarative memory, executive functions, and attention with
the poorest being in probands (i.e., SCH-P, BD-P with psychosis), inter-
mediate in FDR of the psychosis spectrum, and highest in the FDR of the
nonpsychotic spectrum disorder, supporting the notion that cognitive
function in BD and SCH defines a psychosis continuum [51]. Structural
equation modeling of cognitive data from 331 twins/siblings showed that
illness state and concordance for BD had a modest impact of verbal
episodic memory and spatial working memory on the bipolar diathesis;
IQ and visual-spatial learning, however, were associated with genetic
diathesis to BD and with nonaffective symptomatology, also supporting
the notion of psychosis continuum [52].
In an extensive review of studies investigating neurocognitive deficits
in premorbid, high-risk and first-episode BD in comparison to outcome
studies in SCH, Bora proposed a model where only BD-P who are prone
to psychosis may show premorbid neurodevelopmental cognitive deficits
similar to SCH. In the absence of psychosis and neurodevelopmental
deficits, BD-associated temperamental characteristics set the stage be-
tween supranormal premorbid cognition and risk for BP [53••]. Exam-
ination of the cognitive profiles of at-risk individuals for BD and BD-P
did not appear to support previous suggestions of progressive cognitive
decline in BD with illness development [18].
In summary, deficits in executive function, response inhibition, verbal
memory/learning, verbal fluency, processing speed, and verbal fluency
seem to be promising cognitive markers for risk of developing BD.
However, there are limitations in the literature related to the variability
of the tests used in measuring the same cognitive domains by different
groups, inclusion of varying age groups, nonstandardized definition and
use of mixed groups of at-risk individuals (i.e., offspring, siblings, par-
ents), small sample size, and not accounting for the presence of history
of psychosis. Such methodological issues cause inconsistencies in the
findings and difficulty in interpreting the corresponding functional def-
icits. Data are still limited on the presence and pattern of premorbid
cognitive impairment in the risk population. Findings obtained from
cross-sectional studies without controlling for premorbid cognitive im-
pairment may exaggerate the magnitude and misidentify the type of
cognitive deficits to be used as markers for risk of BD. Although it
may not be specific to BD, the effect of deficits in processing speed on
other test performance in patients and to a less extend in the risk groups
and controls [54] should be taken into consideration.
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Brain imaging and risk for BD
Structural imaging findings
Gray matter (GM) abnormalities
In a recent meta-analysis of data from structural and functional imaging
studies, the GM volume of individuals at risk for BD did not differ signif-
icantly from healthy controls, including regions traditionally associated
with BD, such as the striatum, thalamus, amygdala, hippocampus, and
pituitary. The results of this meta-analysis challenge the notion that brain
morphology can yield endophenotypic markers for BD. The authors also
capitalize on the susceptibility of the hippocampus to nongenetic/
environmental factors as obstetric complications and stress-induced exces-
sive glucocorticoid exposure. They also draw attention to an association
between inconsistent pituitary findings and state-dependent cortisol ab-
normalities in mood disorders [55]. Assessment of dexamethasone-
suppression-CRH test in high-risk individuals who developed an affective
disorder in a 10-year follow-up period revealed no premorbid differences in
their cortisol response compared to healthy controls [56]. Dysregulated
hypothalamo-pituitary-adrenal ( HPA) axis abnormalities in BD can be
regarded as a neurobiological scar developing during the course of affective
disorders rather than a neuroendocrine vulnerability marker [56]. A later
review on studies investigating cortical or subcortical GM abnormalities in
BD-FDR shows that findings on various brain regions across studies are
inconsistent except for larger insular cortex volumes in adult first-degree
relatives and larger right inferior frontal gyrus in BD offspring, in compar-
ison to healthy controls [57].
Recent studies support the above findings with larger inferior frontal gyrus,
left insula, smaller cerebellar, and left orbitofrontal gyrus GM volumes
being shared both in BD-P and their FDR [58–60], and larger
parahippocampal and left dorsolateral prefrontal cortex appeared only in
BD-FDR [58, 59].
It is worth remembering that the inferior frontal gyrus has a pivotal role in
response inhibition and emotion regulation, both of which have been
suggested as candidate endophenotypes for BD whereas the cerebellum has
extensive connections to brain areas that are involved in cognition and
behavior including the prefrontal cortex, anterior cingulate, and limbic sys-
tem through cortico-ponto-cerebellar and cerebello-thalamo-cortical path-
ways. The cerebellum also has a homeostatic role in affect regulation in
addition to motor functions [59].
Despite an association between genetic liability for BD and GM volumes in
regions of the anterior cingulate cortex, ventral striatum,medial frontal gyrus,
right precentral gyrus, right insular cortex, and medial orbital gyrus [57], the
absence of evidence for GM abnormalities and contradictory findings [61,
62] across studies in BD-FDR may be due to nongenetic factors such as age,
clinical features,medication, duration illness, pubertal stage, and age of onset
[63–67]. Increased GM volume or thickness of these regions may be conse-
quent of neuroprotective compensatory mechanisms or abnormal brain
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maturation due to the maladaptive pruning in at-risk group or may be
associated with resilience [59].
The search of a relationship between neuroanatomical changes and genetic
risk for BD or SCH showed a specific association between SCH and distrib-
uted GM volume loss in the bilateral fronto-striato-thalamic and left lateral
temporal regions and enlarged lateral ventricles; genetic risk for BD was
specifically associated with GM deficits in the right anterior cingulate gyrus
and ventral striatum [55].
White matter (WM) abnormalities
There is a limited number of diffusion tensor imaging (DTI) studies of
unaffected FDR of BD-P. Some studies found abnormalities in the superior
longitudinal fasciculus, inferior longitudinal fasciculus, corpus callosum,
right uncinate fasciculus, right inferior fronto-occipital fasciculus, right
anterior limb of internal capsule, and thalamic radiation in both BD-P and
BD-FDR [68•, 69], while two studies did not find any abnormalities in
older relative groups compared with controls [70, 71]. A population-based
study showed abnormalities in similar white matter tracts in adolescents
with subthreshold bipolar symptoms [72]. These tracts connect regions
implicated in the identification and regulation of emotion, attention, im-
pulsivity, response inhibition, set shifting, and risk-taking [68•]. Decreased
WMvolume is highly associatedwith genetic risk and familiality in BD [70–
74]. However, the results are neither consistent nor robust enough to
indicate replicable WM abnormalities in BD-FDR, thus not supportive of
the WM abnormalities as an endophenotype of BD, whereas more WM
abnormalities in SCH conform better to the concept of endophenotype
[68•, 73].
Functional neuroimaging
Recent years have witnessed the publication of a sizeable number of task and
resting state fMRI in BD-P and their FDR in comparison to healthy controls.
Resting state
Resting state connectivity between the frontal cortex and basal ganglia or
limbic/paralimbic regions was shown to be altered in a nonspecific fashion
in unaffected BD-FDR [75•]. Solé-Padullés et al. found no connection
differences between any regions in BD-FDR compared with SCH-FDR and
healthy controls [76].
Cognitive task—fMRI studies
When reviewing the relevant studies, we found that patients and their
parents show activation differences in the frontal cortex, insula, amygdala,
parietal cortex, and cingulate cortex as well as connectivity defects between
these regions [55, 75•]. Hyperactivation of inferior frontal gyrus (including
ventrolateral prefrontal cortex and orbitofrontal cortex) and hypoactivation
of insula, amygdala, basal ganglions, and limbic system, which were
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signified in at-risk group, are interpreted as compensatory mechanisms
[75•, 77, 78]. An fMRI study found differential effects of the DISC1
Leu607Phe polymorphism on the left pre/postcentral gyrus, extending to
inferior frontal gyrus in FDR of BD and SCH during language task [79].
However, relatively small sample sizes of the studies limit the generaliz-
ability of the findings.
Emotional task—fMRI studies
Studies which investigated neural substrate of emotional dysregulation in
risk groups for BD showed altered activity in insula and ventrolateral
prefrontal cortex, dysfunctional connectivity in orbitofrontal cortex-amyg-
dala, and impairment in downregulation of amygdala [75•, 77, 80–83].
Breakspear et al. showed impaired hierarchical model (dorsolateral pre-
frontal cortex-inferior frontal gyrus-anterior cingulate cortex) and reduced
activity of inferior frontal gyrus in BD relatives [84]. In the risk group, the
change produced by the negative affect in the brain regions was more
evident than the positive affect [81, 83]. This is an important finding,
yielding a new research area in the light of the fact that response to positive
affect is more sensitive to environmental factors and that it could easily be
lost compared to the control group [81, 83].
In summary, fMRI studies present alterations in the activity of the same
regions involved in the pathophysiology of BD, namely the inferior frontal
gyrus, medial prefrontal cortex, and limbic area particularly in the amyg-
dala, in unaffected BD-FDR, in comparison to healthy controls.
Genetics and white matter neuroimaging in the risk for BD
Studies combining genetics and neuroimaging demonstrated association be-
tween decreasedWM in BD-FDR and disrupted NRG1-ErbB4, calcium signaling
(CACNA1C), phosphatidylinositol, and CAMs pathways [74, 85]. These path-
ways relate to WM development, neuronal plasticity, regulation of neurotrans-
mitter release, and cell adhesion [74]. Another study reported an association
between FA reduction in the WM tracts which are involved in the pathophys-
iology of BD and higher polygenic risk scores in affected but not in unaffected
relatives [86], which suggest that WM abnormalities are closely linked to
expression of psychopathology rather than genetic risk per se.
Overall, there are discrepancies in the results from both structural and
functional imaging studies despite promising findings identifying risk
markers for BD. Different imaging techniques that had been applied, hetero-
geneous clinical and demographical profiles of the participants, small sample
size, variability of the tasks, heterogeneity of the definition of the risk groups
(offspring vs. siblings vs. parents, vs. mixed group of FDR), presence of
subsyndromal symptoms in the risk groups in some studies as well as
variability in age of the participants contribute to difficulties in identifying
a specific pattern of alterations for individuals at risk. Also, the effects of
environmental factors and the association between clinical features and MRI
findings are not well known. The absence of fMRI studies investigating social
cognition, risk-taking, and response inhibition, is also noteworthy.
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Inflammation, oxidation, neurotrophins, and other mediators and risk for BD
Exploration of the inflammatory processes on the neuronal function of risk
groups is important for a better understanding of the molecular basis of risk for
BD as accumulating data implicate these processes in the pathogenesis of BD.
Among several molecules which are suggested to be involved in the patho-
genesis of BD and are known to be involved in inflammation (interleukin 1,
interleukin 6 (IL-6), interleukin 10, interleukin 17, interferon gamma), oxida-
tive stress (thiobarbituric acid reactive substances, protein carbonyl content),
and neurotrophins (BDNF), only IL-6 levels have been found to be significantly
higher in BD-P compared to BD-FDR [87]. However, increased IL-6 and BDNF
plasma levels have been reported in BD offspring compared with healthy
controls. High-risk offspring that appeared to have prodromal symptoms pre-
sented with higher plasma levels of IL-6 and BDNF than high-risk offspring that
appeared asymptomatic or mildly symptomatic [88].
In a prospective follow-up, BDoffspring showed increased proinflammatory
gene expression in monocytes during adolescence, but not in adulthood [89].
Specifically, in that study, BD offspring had persistent monocyte activation
during adolescence and early adulthood as shown by increased cytokine
pentraxin-related protein (PTX3) levels and T-regulatory cells and decreased
effector T cells (Th1 and Th17). Despite decreased serum levels of BDNF,
normal levels of chemokine (C-C motif) ligand 2 (CCL2), and S100 calcium-
binding protein B (S100B) during adolescence, BD offspring showed increased
levels of CCL2, BDNF, and S100B in adulthood [89]. These findings suggest an
abnormal neuroimmune state in BD offspring, which followed a dynamic
course from adolescence into adulthood.
Most recently, plasma levels of lipid peroxidation (lipid hydroperoxide and
4-hydroxy-2-nonenal, 8-isoprostane), protein oxidation (protein carbonyls),
and inflammation (interleukin 1, interleukin 6, interleukin 10, interferon gam-
ma, TNF alfa) were assessed in four groups of adolescents (9–20 years of age),
consisting of high-risk offspring, ultrahigh-risk offspring, first-episode BD pa-
tients, and healthy controls [90]. The levels of lipid hydroperoxide, an early
stage lipid peroxidation marker, showed a decreasing trend along the spectrum
of risk for BD-I, while there was no difference in the late stage lipid peroxidation
markers (4-hydroxy-2-nonenal, 8-isoprostane), protein carbonyls, and inflam-
matory markers among groups [90].
Serum BDNF levels were found to be decreased [91] or unchanged [92, 93] in
BD-P and BD-FDR compared to healthy controls. Duffy et al. reported that the
BDNF genotype significantly moderates the association between high-risk status
for both gene expression and protein levels in BD offspring [88]. Corresponding-
ly, anxiety symptoms were associated with the BDNF risk genotype only in BD
offspring but not in healthy controls, and BD offspring with the val/val genotype
showed higher anxiety symptoms than BD offspring with other genotypes [94].
Ferensztajn et al. reported higher BDNF andmatrixmetalloproteinase-9 levels
and lower IL-6 levels in the offspring of BD-P who were excellent lithium
responders compared to the offspring of BD-P who were lithium nonresponders
[95].
Comparison of biomarkers related to oxidative stress [8-hydroxy-2′-
deoxyguanosine (8-OHdG), mitochondrial complex 1 activation, and
glutathione peroxidase activities] and global DNA methylation (5-
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methylcytosine) between lithium responder BD-P, BD-FDR and healthy
controls showed that BD-FDR have decreased global methylation, in-
creased glutathione peroxidase activity, and no change in 8-OHdG or
in mitochondrial complex 1 activity [96].
These results show that risk groups for BD present with altered
immune and neurochemical modulation. However, the findings are
preliminary, and studies on well-defined and clinically homogeneous
risk groups, particularly in prospective design to understand the risk
and defense mechanisms, are needed.
Conclusion and future directions
Prospective long-term follow-up studies using multimodal (i.e., combi-
nation of imaging, cognitive, neurochemical, and genetic assessment of
the participants) and standardized techniques (i.e., the same set of
cognitive tasks per domain) in well-defined at-risk populations, control-
ling for age and gender distribution as well as for the presence of
symptoms, are needed for better understanding of the neurobiology of
risk for BD [97]. Operationalized criteria for defining risk and resilience
markers would also assist in improving our understanding of the com-
plex changes observed in patients and their relatives. This would also
foster further research into disambiguating compensatory from patholog-
ical processes. It is unclear whether disease-specific biomarkers can in-
deed be identified as most indications point to significant overlap
between disorders which has generally motivated a trans-diagnostic ap-
proach to psychiatric research. Another unmet need is the information
on interaction between immune and neurochemical alterations and cog-
nitive and structural/functional changes. Studies exploring the associa-
tions between neurochemical, cognitive, and imaging are needed. Multi-
center, population-based studies with large sample size allowing for
homogeneous subgroup analysis (i.e., relatives of BD type I vs. type II,
psychotic vs. nonpsychotic, offspring vs. sibling, symptomatic vs. asymp-
tomatic, adolescent vs. adult; treatment responder vs. nonresponder)
searching for cognitive, imaging, and neurochemical modulatory markers
for risk for BD in an integrative way will immensely contribute to the
field.
Highlights of the review
The review includes data on cognitive functions, structural and functional
imaging, and neurochemical modulation as potential markers for risk and
resilience for BD in an integrative way. The most recent data in each respective
field has been included in the review besides meta-analysis and systematic
reviews.
Despite inconsistencies, compiling data reveals cognitive and imaging
markers for risk and to a less extent resilience of BD. Findings on neural
modulation markers are preliminary and require further studies. Methodolog-
ical issues causing obstacle in interpretation of the existing data have been
considered.
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